Esperion Corp (ESPR): Market Cap to Revenue Ratio

Symbol and logo of brand Esperion Therapeutics, Inc. (ESPR)

How can cholesterol be effectively managed without statins? Esperion Therapeutics (ESPR) is developing cutting-edge solutions that have earned recognition from cardiologists. The company's average P/S reflects the current market valuation of the business, with the indicator standing at 2.00. Strict FDA certifications and patent protection ensure resilience. A developed network of European plants and a sophisticated international distribution system guarantee supply stability.

ESPR: Esperion Corp Market Cap to Revenue 07/04/2022 - 07/25/2026

Analytical breakdowns for Esperion Therapeutics Inc (ESPR)

- current quotes and average value forecast:
Market Price esperion.com|ESPR - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Esperion Therapeutics Inc|ESPR - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Esperion Therapeutics|ESPR - Company Net Assets|Market Cap to Book Value Multiple esperion.com|ESPR - Company Total Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Esperion Therapeutics|ESPR - Long-Term Debt to Capital|Current Liabilities to Capital Esperion Corp|ESPR - Company Debts|Debt to Net Assets Ratio Esperion Therapeutics Inc|ESPR - Company Long-Term Debts|Company Short-Term Debts Esperion Therapeutics|Critical Liquidity Ratio esperion.com
- earnings and valuation multiples information:
ESPR - Net Profit|Expected Net Profit Esperion Therapeutics|ESPR - Price to Earnings Ratio|Forward P/E Multiple Esperion Therapeutics, Inc.|ESPR - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Esperion Therapeutics Inc|ESPR - Operating profit EBITDA|Net earnings per share for the last four quarters Esperion Therapeutics|ESPR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months esperion.com|ESPR - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Esperion Therapeutics
- sales revenue and business income indicators:
ESPR - Revenue and Sales Volume|Company Expected Sales Volume esperion.com|ESPR - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Esperion Therapeutics Inc
Fundamental company analysis:esperion.com, ESPR
Finished products of Esperion

The P/S multiple reflects the market valuation of the operational efficiency of Esperion Therapeutics (ESPR), comparing the total business value to the volume of generated sales. By analyzing the current P/S multiple, an investor assesses the premium for the uniqueness of the drug Nexletol against competition from statins, where inflated values signal that the asset is overbought, while low values indicate stagnation of the company's commercial potential.

Competing companies

REGN - Price to Sales|Price-to-Revenue Ratio iRhythm IRTC|LNTH: Market Cap to Revenue Ratio|MLYS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HTFL (Heartflow Inc)|KMTS (Kestra Medical Technologies) - Market Cap to Revenue|AMRN: Market Cap to Sales Volume|AVR (Anteris) - P/S Multiple|TNYA: Market Capitalization-to-Revenue Ratio|P/S Multiple CVRX|MIST - Price to Sales|Price-to-Revenue Ratio Cardiol Therapeutics Inc. CRDL|Market Capitalization-to-Revenue Ratio BEAT|Tenax Therapeutics, Inc. - P/S Multiple|ADGM - P/S Multiple|BioCardia, Inc (BCDA) - Price-to-Revenue Ratio|Price-to-Sales Ratio VTAK (Catheter Precision Corporation)|ABIO (ARCA Biopharma Inc) - P/S Multiple|Price to Sales Acasti ACST|Market Cap to Revenue AVTE (Aerovate Therapeutics, Inc.)|P/S Multiple vervetx.com (VERV)|Windtree Therapeutics, Inc. - Market Cap to Revenue